Characterization of pericardial and plasma ghrelin levels in patients with ischemic and non-ischemic heart disease

Sax, Balázs; Merkely, Béla; Turi, Katalin; Nagy, Alexandra; Ahres, Abdelkrim; Hartyánszky, István; Hüttl, Tivadar; Szepes, Zoltán; Cseh, Károly; Kékesi, Violetta

doi:10.1016/j.regpep.2013.08.003

Cited by 10 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sax et al found that pericardial active ghrelin concentration and the pericardial-to-plasma ghrelin ratio were elevated in IHD patients, compared to non-ischaemic subjects, and suggested an increased ghrelin production by the chronically ischaemic myocardium. 34 Gnanapavan et al demonstrated mRNA expression of ghrelin in the myocardium and veins. They determined that GHS-R1a was expressed in the myocardium and not the veins, while GHS-R1b was expressed in both.…”

Section: Discussionmentioning

confidence: 99%

Saliva/serum ghrelin, obestatin and homocysteine levels in patients with ischaemic heart disease

Kılıç

Dağlı

Aydın

et al. 2017

CVJA

View full text Add to dashboard Cite

SummaryBackground:We aimed to compare ghrelin, obestatin, homocysteine (Hcy), vitamin B12 and folate levels in the serum and saliva of ischaemic heart disease patients.Methods:Serum and saliva were collected from 33 ischaemic heart disease (IHD) patients and 28 age- and body mass index-matched healthy individuals. Levels of acylated and desacylated ghrelin, obestatin and Hcy were determined using the ELISA method.Results:Acylated ghrelin, desacylated ghrelin and obestatin levels in the saliva were found to be higher than those in the serum of the control group, while acylated and desacylated ghrelin levels in the saliva were significantly lower than those in the serum. Obestatin levels were higher in IHD patients (p = 0.001). Saliva and serum vitamin B12 and folate levels in IHD patients were significantly lower than in the control group (p = 0.001).Conclusions:It was determined that serum ghrelin levels increased in ischaemic heart disease patients, while serum levels of obestatin decreased.

show abstract

Section: Discussionmentioning

confidence: 99%

Saliva/serum ghrelin, obestatin and homocysteine levels in patients with ischaemic heart disease

Kılıç

Dağlı

Aydın

et al. 2017

CVJA

View full text Add to dashboard Cite

show abstract

“…Genetic variants of the ghrelin system are associated with susceptibility to MI and coronary artery disease by investigating seven single-nucleotide polymorphisms (SNPs) covering the GHSR region as well as eight SNPs across the ghrelin gene region in MI patients [51,52]. Increased pericardial active ghrelin content were found in ischemic heart disease patients, suggesting an increased ghrelin production of the chronically ischemic myocardium [53]. Furthermore, Serum ghrelin and VEGF-A levels were significantly higher in the good collateral group with severe coronary artery disease than that in the poor collateral group [54].…”

Section: The Relation Between Ghrelin and Coronary Artery Diseasementioning

confidence: 99%

Research progress of ghrelin on cardiovascular disease

Yuan

Zhong

2021

Bioscience Reports

View full text Add to dashboard Cite

Ghrelin, a 28-aminoacid peptide, was isolated from the human and rat stomach and identified in 1999 as an endogenous ligand for the growth hormone secretagogue-receptor (GHS-R). In addition to stimulating appetite and regulating energy balance, ghrelin and its receptor GHS-R1a have a direct effect on the cardiovascular system. In recent years, it has been shown that ghrelin exerts cardioprotective effects, including the modulation of sympathetic activity and hypertension, enhancement of the vascular activity and angiogenesis, inhibition of arrhythmias, reduction in heart failure and inhibition of cardiac remodeling after myocardial infarction (MI). The cardiovascular protective effect of ghrelin may be associated with anti-inflammation, anti-apoptosis, inhibited sympathetic nerve activation, regulated autophagy, and endothelial dysfunction. However, the molecular mechanisms underlying the effects of ghrelin on the cardiovascular system have not been fully elucidated, and no specific therapeutic agent has been established. It is important to further explore the pharmacological potential of ghrelin pathway modulation for the treatment of cardiovascular diseases.

show abstract

“…Ghrelin is a 28-amino-acid peptide hormone and is posttranslationally modified on Ser3 by octanoylation, a modification that is critical for binding to GHSR1a [ 4 ]. Both the acylated and nonacylated forms have been found in pericardial fluid [ 5 ], indicating that the human heart produces and secretes both forms. Both ghrelin and GHSR1a are present in the myocardium [ 6 , 7 ] and may represent a ghrelin/GHSR1a system independent of the ghrelin/GHSR1a system that regulates energy expenditure.…”

mentioning

confidence: 99%

Changes in the Cardiac GHSR1a-Ghrelin System Correlate With Myocardial Dysfunction in Diabetic Cardiomyopathy in Mice

Sullivan

McGirr

et al. 2017

Journal of the Endocrine Society

View full text Add to dashboard Cite

Ghrelin and its receptor, the growth hormone secretagogue receptor 1a (GHSR1a), are present in cardiac tissue. Activation of GHSR1a by ghrelin promotes cardiomyocyte contractility and survival, and changes in myocardial GHSR1a and circulating ghrelin track with end-stage heart failure, leading to the hypothesis that GHSR1a is a biomarker for heart failure. We hypothesized that GHSR1a could also be a biomarker for diabetic cardiomyopathy (DCM). We used two models of streptozotocin (STZ)-induced DCM: group 1, adult mice treated with 35 mg/kg STZ for 3 days; and group 2, neonatal mice treated with 70 mg/kg STZ at days 2 and 5 after birth. In group 1, mild fasting hyperglycemia (11 mM) was first detected 8 weeks after the last injection, and in group 2, severe fasting hyperglycemia (20 mM) was first detected 1 to 3 weeks after the last injection. In group 1, left ventricular function was slightly impaired as measured by echocardiography, and Western blot analysis showed a significant decrease in myocardial GHSR1a. In group 2, GHSR1a levels were also decreased as assessed by Cy5-ghrelin(1–19) fluorescence microscopy, and there was a significant negative correlation between GHSR1a levels and glucose tolerance. There were significant positive correlations between GHSR1a and ghrelin and between GHSR1a and sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a), a marker for contractility, but not between GHSR1a and B-type natriuretic peptide, a marker for heart failure. We conclude that the subclinical stage of DCM is accompanied by alterations in the myocardial ghrelin-GHSR1a system, suggesting the possibility of a biomarker for DCM.

show abstract

Characterization of pericardial and plasma ghrelin levels in patients with ischemic and non-ischemic heart disease

Cited by 10 publications

References 46 publications

Saliva/serum ghrelin, obestatin and homocysteine levels in patients with ischaemic heart disease

Saliva/serum ghrelin, obestatin and homocysteine levels in patients with ischaemic heart disease

Research progress of ghrelin on cardiovascular disease

Changes in the Cardiac GHSR1a-Ghrelin System Correlate With Myocardial Dysfunction in Diabetic Cardiomyopathy in Mice

Contact Info

Product

Resources

About